DE69634300D1 - Gentherapie mit hilfe von schaf-adenoviralen vektoren - Google Patents

Gentherapie mit hilfe von schaf-adenoviralen vektoren

Info

Publication number
DE69634300D1
DE69634300D1 DE69634300T DE69634300T DE69634300D1 DE 69634300 D1 DE69634300 D1 DE 69634300D1 DE 69634300 T DE69634300 T DE 69634300T DE 69634300 T DE69634300 T DE 69634300T DE 69634300 D1 DE69634300 D1 DE 69634300D1
Authority
DE
Germany
Prior art keywords
cell
pct
nucleic acid
acid sequence
help
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69634300T
Other languages
English (en)
Other versions
DE69634300T2 (de
Inventor
Wayne Both
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Commonwealth Scientific and Industrial Research Organization CSIRO
Original Assignee
Commonwealth Scientific and Industrial Research Organization CSIRO
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Commonwealth Scientific and Industrial Research Organization CSIRO filed Critical Commonwealth Scientific and Industrial Research Organization CSIRO
Publication of DE69634300D1 publication Critical patent/DE69634300D1/de
Application granted granted Critical
Publication of DE69634300T2 publication Critical patent/DE69634300T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
    • C12N2810/6018—Adenoviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69634300T 1995-08-14 1996-08-14 Gentherapie mit hilfe von schaf-adenoviralen vektoren Expired - Lifetime DE69634300T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPN477695 1995-08-14
AUPN4776A AUPN477695A0 (en) 1995-08-14 1995-08-14 Gene therapy
PCT/AU1996/000518 WO1997006826A1 (en) 1995-08-14 1996-08-14 Gene therapy using ovine adenoviral vectors

Publications (2)

Publication Number Publication Date
DE69634300D1 true DE69634300D1 (de) 2005-03-10
DE69634300T2 DE69634300T2 (de) 2005-12-22

Family

ID=3789107

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69634300T Expired - Lifetime DE69634300T2 (de) 1995-08-14 1996-08-14 Gentherapie mit hilfe von schaf-adenoviralen vektoren

Country Status (10)

Country Link
US (1) US6020172A (de)
EP (1) EP0851769B1 (de)
JP (1) JP4733795B2 (de)
AT (1) ATE288496T1 (de)
AU (2) AUPN477695A0 (de)
CA (1) CA2229631C (de)
DE (1) DE69634300T2 (de)
ES (1) ES2237772T3 (de)
NZ (1) NZ315295A (de)
WO (1) WO1997006826A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7037712B2 (en) * 1994-07-26 2006-05-02 Commonwealth Scientific And Industrial Research Organisation DNA encoding ovine adenovirus (OAV287) and its use as a viral vector
FR2723697B1 (fr) * 1994-08-17 1996-09-20 Rhone Poulenc Rorer Sa Methode de traitement de la restenose par la therapie genique
AU767975B2 (en) 1998-09-11 2003-11-27 Genvec, Inc. Alternatively targeted adenovirus
US6440944B2 (en) 1998-10-16 2002-08-27 Genvec, Inc. Methods of administering adenoviral vectors
JP2002535997A (ja) * 1999-02-02 2002-10-29 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク 細胞の老化および細胞の最終分化の際に向上した発現を示す遺伝子、およびその使用
US7074400B1 (en) * 1999-03-01 2006-07-11 The Commonwealth Of Australia Regulatory constructs comprising intron 3 of prostate specific membrane antigen gene
AU6280600A (en) * 1999-08-06 2001-03-05 Develogen Aktiengesellschaft Fur Entwicklungsbiologische Forschung Non-human adenoviral vector for gene transfer, its use and the production thereof
US7115391B1 (en) 1999-10-01 2006-10-03 Genovo, Inc. Production of recombinant AAV using adenovirus comprising AAV rep/cap genes
DE10006886A1 (de) * 2000-02-16 2001-08-23 Hepavec Ag Fuer Gentherapie Nichthumaner helferabhängiger Virusvektor
AU2001261650A1 (en) * 2000-05-15 2001-11-26 Geron Corporation Ovine tissue for xenotransplantation
EP1301612A2 (de) * 2000-05-31 2003-04-16 Genvec, Inc. Verfahren und zusammenfassung zur zielrichtung von adenoviralen vektoren
AU2001263689B2 (en) 2000-05-31 2007-03-22 University Of Saskatchewan Modified bovine adenovirus having altered tropism
EP1453536A4 (de) 2001-12-12 2009-08-26 Mayne Pharma Int Pty Ltd Zusammensetzung zur konservierung von viren
AU2003241268A1 (en) * 2002-02-05 2003-09-09 Cornell Research Foundation, Inc. Adenoviral vector with replication-dependent transgene expression
AUPS145602A0 (en) * 2002-03-28 2002-05-09 Commonwealth Scientific And Industrial Research Organisation Composition and method for killing tumours
FR2842823A1 (fr) * 2002-07-25 2004-01-30 Inst Nat Sante Rech Med Adenovirus modifies pour le ciblage des lymphocytes b
AU2003300076C1 (en) 2002-12-30 2010-03-04 Angiotech International Ag Drug delivery from rapid gelling polymer composition
US7342107B2 (en) 2004-05-27 2008-03-11 Centocor, Inc. Cynomolgus prostate specific antigen
US20050276758A1 (en) * 2004-06-15 2005-12-15 Marshall Deborah J Method for screening agents against human prostate disease
US9073980B2 (en) 2009-03-02 2015-07-07 The Regents Of The University Of California Tumor selective E1a and E1b mutants
KR102089121B1 (ko) 2013-03-14 2020-03-13 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 종양살상형 아데노바이러스 조성물
EP3390428B1 (de) 2016-02-23 2019-09-25 Salk Institute for Biological Studies Test mit hohem durchsatz zur messung der adenovirusreplikationskinetik
CN117384961A (zh) 2016-02-23 2024-01-12 萨克生物研究学院 对病毒动力学影响最小的治疗性腺病毒中的外源基因表达
CA3038526A1 (en) 2016-09-27 2018-04-05 Epicentrx, Inc. Immunomodulatory fusion proteins
CN110062630A (zh) 2016-12-12 2019-07-26 萨克生物研究学院 肿瘤靶向合成腺病毒及其用途
CN111511769B (zh) 2017-09-27 2024-05-24 埃皮辛特瑞柯斯公司 免疫调节性融合蛋白

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2705361B1 (fr) * 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
SK282843B6 (sk) * 1993-07-13 2002-12-03 Rhone-Poulenc Rorer S. A. Defektný rekombinantný adenovírus a farmaceutický prostriedok s jeho obsahom
US5552311A (en) * 1993-09-14 1996-09-03 University Of Alabama At Birmingham Research Foundation Purine nucleoside phosphorylase gene therapy for human malignancy
US5820868A (en) * 1993-12-09 1998-10-13 Veterinary Infectious Disease Organization Recombinant protein production in bovine adenovirus expression vector system
AU686844B2 (en) * 1994-07-26 1998-02-12 Commonwealth Scientific And Industrial Research Organisation DNA encoding ovine adenovirus (OAV287) and its use as a viral vector
AUPM710194A0 (en) * 1994-07-26 1994-08-18 Commonwealth Scientific And Industrial Research Organisation Virus vector
FR2724945B1 (fr) * 1994-09-27 1996-12-27 Centre Nat Rech Scient Vecteurs viraux et utilisation en therapie genique
FR2725726B1 (fr) * 1994-10-17 1997-01-03 Centre Nat Rech Scient Vecteurs viraux et utilisation en therapie genique
FR2726285B1 (fr) * 1994-10-28 1996-11-29 Centre Nat Rech Scient Adenovirus depourvus de particules contaminantes viables, preparation et utilisation

Also Published As

Publication number Publication date
CA2229631C (en) 2011-05-24
WO1997006826A1 (en) 1997-02-27
NZ315295A (en) 1999-09-29
EP0851769B1 (de) 2005-02-02
CA2229631A1 (en) 1997-02-27
EP0851769A4 (de) 1999-01-07
ATE288496T1 (de) 2005-02-15
US6020172A (en) 2000-02-01
AUPN477695A0 (en) 1995-09-07
EP0851769A1 (de) 1998-07-08
AU6696696A (en) 1997-03-12
DE69634300T2 (de) 2005-12-22
JPH11511139A (ja) 1999-09-28
AU708870B2 (en) 1999-08-12
ES2237772T3 (es) 2005-08-01
JP4733795B2 (ja) 2011-07-27

Similar Documents

Publication Publication Date Title
DE69634300D1 (de) Gentherapie mit hilfe von schaf-adenoviralen vektoren
EP0710288A4 (de) Adenovirale vektoren für die behandlung der hämophilie
AP1678A (en) Novel modified nucleic acid sequences and methods for increasing mRNA levels and protein expression in cell systems.
ATE335831T1 (de) Nukleinsäurevektor, einen solchen vektor enthaltene verbindung und impfstoff zur immunisierung gegen hepatitis
DK1224314T3 (da) Lentiviralt triplex-DNA samt vektorer og rekombinante celler indeholder lentiviralt triplex-DNA
DE69535703D1 (de) Aav-vermittelte überbringung von dna in zellen des nervensystems
Dhar et al. Nucleotide sequence of the DNA replication origin for human papovavirus BKV: sequence and structural homology with SV40
ZA942778B (en) Recombinant viruses, and their preparation and use in gene therapy.
DK0797678T3 (da) Hybrid adenovirus-AAV-virus og fremgangsmåder til anvendelse af dette
DE60228066D1 (de) Onkolytische adenovirale vektoren
CA2311643A1 (en) Compositions and methods for inducing gene expression
HK1014993A1 (en) Rectroviral vectors
ATE369384T1 (de) Expression und export von interferon-alpha proteinen als fc fusionsproteine
DK1783225T3 (da) Strukturprotein fra AAV, dets fremstilling og anvendelse
EP0804609A4 (de) NEUARTIGE AUF p53 ANSPRECHENDE GENE
ATE345819T1 (de) Kapsidmodifiziertes rekombinantes adenovirusund verfahren zu dessen anwendung
ATE384263T1 (de) Verfahren zur bestimmung von biologischen agenzien in lebenden zielzellen
DK1045901T3 (da) Ribozymale nucleinsyrer, der spalter CCR5 eller CXCR4
AUPM710194A0 (en) Virus vector
ATE377087T1 (de) Verfahren zur herstellung eines rekombinanten rinderadenovirus-vektors
PT1140023E (pt) Formulacoes cocleares integrativas de proteina-adn e metodos de transformacao celular
FI924494A0 (fi) Oekad produktion av avsoendrarde proteiner i eukaryotiska rekombinantceller
HUP9904201A1 (hu) Génterápiában használható, egy exogén nukleinsavat genomjában beépítve tartalmazó rekombináns vírus és egy nem virális és nem plazmid transzfektáló szer kombinációját tartalmazó transzfektáló készítmény
WO2002083896A3 (en) Recombinant segmented negative strand virus with a duplicated 3' noncoding flanking sequence, and therapeutic compositions containing the same
FI964784A (fi) Yhdistelmä-DNA-viruksia, valmistus ja käyttö geeniterapiassa

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: GRAF VON STOSCH PATENTANWALTSGESELLSCHAFT MBH, 805